Business
Nurix Therapeutics Announces Presentations at the 67th American Society of Hematology (ASH) Annual Meeting
SAN FRANCISCO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery,
About this update from Nurix Therapeutics, Inc.
[{"type":"text","content":"SAN FRANCISCO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in oncology and autoimmune disease, today announced that updated clinical data from the NX-5948-301 Phase 1a/1b clinical trial have been selected for presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 6 – 9, 2025, in Orlando, Florida. The data will be featured in two presentations: an oral presentation with new results in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and a poster presentation with updated results in patients with Waldenström macroglobulinemia. In addition to these clinical presentations, Nurix and its collaborators will also present new mechanistic insights into resistance to Bruton’s tyrosine kinase (BTK) targeted therapies at a separate ASH poster session, highlighting discoveries that expand the understanding of BTK biology. Oral Presentation Details: Title: Bexobrutideg (NX-5948), a Novel Bruton’s Tyrosine Kinase (BTK) Degrader, Demonstrates Rapid and Durable Clinical Responses in Relapsed / Refractory Chronic Lymphocytic Leukemia (CLL): New and Updated Findings from an Ongoing Phase 1a/b TrialPresenter: Zulfa Omer, M.D., Assistant Professor Internal Medicine, College of Medicine, University of Cincinnati, Cincinnati, OH, USASession Name: 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Treatment of CLL in Relapse and in Richter TransformationAbstract #: 86Session Date and Time: Saturday, December 6, 2025, 9:30 a.m. – 11:00 a.m. ETPresentation Time: 9:45 a.m. – 10:00 a.m. ETRoom: Orange County Convention Center - W224ABEF Poster Presentation Details Title: Bexobrutideg (NX-5948), a Novel Bruton’s Tyrosine Kinase (BTK) Degrader, Shows High Clinical Activity and Tolerable Safety in Patients with Waldenström Macroglobulinemia: Updated Results from an Ongoing Phase 1a/b StudyPresenter: Scott Huntington M.D., MPH, Associate Professor of Internal Medicine (Hematology), Yale School of MedicineSession Name: 623: Mantle Cell, Follicular, Waldenstrom’s, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster III Abstract # 5359Session Date and Time: Monday, December...